# Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

> **NCT03245450** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 40 (actual)

## Conditions studied

- Refractory or Recurrent Solid Tumors
- Rhabdomyosarcoma
- Non-Rhabdomyosarcoma Soft Tissue Sarcoma
- Ewing Sarcoma

## Interventions

- **DRUG:** Eribulin mesilate
- **DRUG:** Irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT03245450
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-05
- **Primary completion:** 2021-05-17
- **Final completion:** 2021-05-17
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245450, "Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03245450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*